Vigil Neuroscience, Inc. (NASDAQ:VIGL – Get Free Report) CEO Ivana Magovcevic-Liebisch bought 4,000 shares of the business’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $3.75 per share, with a total value of $15,000.00. Following the purchase, the chief executive officer now owns 207,687 shares of […]
Wedbush reiterated their outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL – Free Report) in a report published on Friday, Benzinga reports. Wedbush currently has a $23.00 price objective on the stock. Several other equities analysts have also recently commented on VIGL. JMP Securities began coverage on shares of Vigil Neuroscience in a research report […]
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite falling around 30 points on Friday. Following the market opening Friday, the Dow traded down 0.04% to 34,931.47 while the NASDAQ fell 0.22% to 14,082.87. The S&P 500 also fell, dropping, 0.07% to 4,504.96.
Vigil Neuroscience Inc VIGL shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with…
Vigil Neuroscience Inc (NASDAQ: VIGL) shares are down after the company released interim data from its Phase 2 IGNITE proof-of-concept clinical trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a neurological condition characterized by changes to&nb